Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Advanced sensing features are coming to wearables beginning in 2025 and Penn State’s device, made with laser-modified ...

For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge. A new clinical trial at UVA is aiming to simplify diabetes management by testing an ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Goode, PhD, President & Chief Executive Officer of Glucotrack. "With these positive results, the promise of continuous blood glucose monitoring is one step closer to reality." The prospective single ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...